You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Delivering IL-2 to Tregs
Interleukin-2 (IL-2) not only promotes activation and expansion of conventional T cells but also plays a crucial role in regulating homeostasis and functions of regulatory T (Treg) cells. As expression of the high-affinity IL-2 receptor is largely restricted to Treg cells, engineering IL-2 variants, called muteins, that selectively bind to the high-affinity IL-2 receptor and potentiate Treg functions can be used in the treatment of autoimmune diseases. Here, Khoryati et al. have engineered a murine IL-2 mutein that selectively promotes expansion of Treg cells. They demonstrate that administration of this IL-2 mutein resolved ongoing diabetes in nonobese diabetic mice. This proof-of-principle study raises the possibility that engineered human IL-2 muteins could be used in the treatment of autoimmune diseases.
Abstract
Interleukin-2 (IL-2) controls the homeostasis and function of regulatory T (Treg) cells, and defects in the IL-2 pathway contribute to multiple autoimmune diseases. Although recombinant IL-2 therapy has been efficacious in certain inflammatory conditions, the capacity for IL-2 to also activate inflammatory effector responses highlights the need for IL-2–based therapeutics with improved Treg cell specificity. From a panel of rationally designed murine IL-2 variants, we identified IL-2 muteins with reduced potency and enhanced Treg cell selectivity due to increased dependence on the IL-2 receptor component CD25. As an Fc-fused homodimer, the optimal Fc.IL-2 mutein induced selective Treg cell enrichment and reduced agonism of effector cells across a wide dose range. Furthermore, despite being a weaker agonist, overall Treg cell growth was greater and more sustained due to reduced receptor-mediated clearance of the Fc.IL-2 mutein compared with Fc-fused wild-type IL-2. Preferential Treg cell enrichment was also observed in the presence of activated pathogenic T cells in the pancreas of nonobese diabetic (NOD) mice, despite a loss of Treg cell selectivity in an IL-2R proximal response. These properties facilitated potent and extended resolution of NOD diabetes with infrequent dosing schedules.
- Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
This is an article distributed under the terms of the Science Journals Default License.